<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814723</url>
  </required_header>
  <id_info>
    <org_study_id>2004-002535-12</org_study_id>
    <nct_id>NCT00814723</nct_id>
  </id_info>
  <brief_title>Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk</brief_title>
  <official_title>Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with coronary heart disease (CHD) or CHD equivalent (e. g. diabetes mellitus) often
      have abnormalities in lipids (hypercholesterolemia). Besides, hypercholesterolemia is an
      evident risk factor for atherosclerosis. Hitherto, there are only few studies of patients
      with primary hypercholesterolemia where the combination therapy with statins
      (HMG-Co-reductase inhibitors) and ezetimib was investigated. This combination therapy should
      be more effective in reducing low density lipoprotein cholesterol (LDL-C) and total
      cholesterol levels compared to monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ezetimibe, a cholesterol-absorption inhibitor, significantly lowers low-density lipoprotein
      cholesterol (LDL-C) when administered in addition to statin treatment. The effect of
      ezetimibe on the incidence and progression of vascular disease is elusive. Therefore, our
      objective was to examine the effects of fluvastatin and fluvastatin plus ezetimibe on
      lipoprotein subfractions in patients with diabetes mellitus and/or coronary heart disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>week 6 and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol, triglycerides, HDL-C, lipoprotein subfractions, hs-CRP</measure>
    <time_frame>week 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events, CK elevation, liver enzyme elevation</measure>
    <time_frame>week 6, 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Fluvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluvastatin 80 mg MR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluvastatin + Ezetimibe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluvastatin MR 80 mg plus Ezetimibe 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluvastatin</intervention_name>
    <description>80 mg MR, 12 weeks</description>
    <arm_group_label>Fluvastatin</arm_group_label>
    <other_name>Lescol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvastatin plus ezetimibe</intervention_name>
    <description>fluvastatin 80 mg MR plus ezetimibe 10 mg</description>
    <arm_group_label>Fluvastatin + Ezetimibe</arm_group_label>
    <other_name>Lescol, Ezetrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CHD or CHD equivalent with LDL 100-160 mg/dl

          -  Male or female sex

          -  Normal values of CK, AST and ALT

          -  Normal kidney function

        Exclusion Criteria:

          -  CHD Stage III-IV

          -  St. p. myocardial infarction or coronary artery bypass grafting

          -  Pregnancy or breastfeeding

          -  Premenopausal women without certain contraception

          -  Known hypersensitivity to HMG-CoA reductase inhibitors or ezetimib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winfried März, Prof. , M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Synlab Medizinisches Versorgungszentrum für Labordiagnostik Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Depart. of Internal Medicine, Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2008</study_first_submitted>
  <study_first_submitted_qc>December 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2008</study_first_posted>
  <last_update_submitted>December 24, 2008</last_update_submitted>
  <last_update_submitted_qc>December 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Winfried März</name_title>
    <organization>Medical University of Graz</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Fluvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

